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The xc
  cystine transporter enhances biosynthesis of glutathione, a tripeptide thiol important in drug resistance and cellular defense
against oxidative stress, by enabling cellular uptake of cystine, a rate-limiting precursor. Because it is known to regulate glutathione
levels and growth of various cancer cell types, and is expressed in the pancreas, we postulate that it is involved in growth and drug
resistance of pancreatic cancer. To examine this, we characterised expression of the xc
  transporter in pancreatic cancer cell lines,
MIA PaCa-2, PANC-1 and BxPC-3, as subjected to cystine-depletion and oxidative stress. The results indicate that these cell lines
depend on xc
 -mediated cystine uptake for growth, as well as survival in oxidative stress conditions, and can modulate xc
  expression
to accommodate growth needs. Immunohistochemical analysis showed that the transporter was differentially expressed in normal
pancreatic tissues and overexpressed in pancreatic cancer tissues from two patients. Furthermore, gemcitabine resistance of cells was
associated with elevated xc
  expression and specific xc
  inhibition by monosodium glutamate led to growth arrest. The results suggest
that the xc
  transporter by enhancing glutathione biosynthesis plays a major role in pancreatic cancer growth, therapy resistance and
represents a potential therapeutic target for the disease.
British Journal of Cancer (2008) 99, 464–472. doi:10.1038/sj.bjc.6604485 www.bjcancer.com
Published online 22 July 2008
& 2008 Cancer Research UK
Keywords: pancreatic cancer; cystine transporter; glutathione; drug resistance; xCT
                                               
Pancreatic cancer is the second most common gastrointestinal
malignancy and the fourth leading cause of cancer-related deaths
in the United States (Freelove and Walling, 2006). It is highly
resistant to conventional chemotherapeutic regimens (Zalatnai and
Molnar, 2007) and gemcitabine (GEM), currently the standard
chemotherapeutic agent for treatment of pancreatic cancer, is only
marginally effective (Wolff, 2007). Clearly, there is a critical need
for establishing new targets and approaches for therapy of
pancreatic cancer.
Glutathione (GSH) is a tripeptide thiol consisting of glutamate,
cysteine and glycine, which plays a critical role in cellular defenses
against oxidative stress and toxic compounds (Griffith, 1999). In
cancer cells the GSH levels maintain DNA synthesis, growth and
multidrug/radiation resistance, and sustenance of GSH levels
through GSH biosynthesis is vital for growth and survival of
tumours. As such, GSH is considered an important target in cancer
therapy and various therapeutic approaches based on GSH
depletion of cancer cells have been suggested (Schnelldorfer
et al, 2000; Estrela et al, 2006; Doxsee et al, 2007). Glutathione
biosynthesis is critically dependent on availability of intracellular
cysteine, a major rate-limiting factor (Griffith, 1999). Although
tissues such as the liver can synthesise cysteine from L-methionine
through the transsulphuration pathway (Rosado et al, 2007),
certain experimental cancers (e.g., lymphomas, gliomas) are
incapable of synthesising adequate amounts of the amino acid
for GSH synthesis and hence depend for growth and viability on
uptake of extracellular cysteine or cystine, the oxidised form. In
such cases, reduced cellular uptake of the amino acid can lead to
depletion of intracellular GSH levels and subsequent growth arrest
(Gout et al, 1997; Iwata et al, 1997; Chung et al, 2005).
The xc
  cystine/glutamate antiporter is a plasma membrane
transporter mediating cellular uptake of cystine in exchange for
intracellular glutamate with a stoichiometry of 1:1 (Lo et al, 2008).
It is a member of a family of heterodimeric amino-acid
transporters, plasma membrane proteins composed of a heavy
subunit and a light subunit coupled through a disulphide bridge.
The human xc
  transporter consists of the heavy subunit 4F2hc,
found in a variety of amino-acid transporters, coupled to the light
subunit, xCT, which confers specificity for cystine (Verrey et al,
2004). It has been demonstrated, both in vitro and in vivo that
inhibition of the xc
  transporter in cancer cells depending on
extracellular cystine/cysteine for growth and viability, can lead to
reduced uptake of this amino acid with subsequent depletion of
intracellular GSH levels and growth arrest (Gout et al, 2001; Chung
et al, 2005; Doxsee et al, 2007). For such malignancies the
xc
  transporter therefore represents a potential therapeutic target
(Lo et al, 2008).
Human xCT is expressed in the pancreas, as one of a limited
number of tissues (Bassi et al, 2001). Although xc
  activity has been
investigated in normal pancreatic cell lines (Sato et al, 1998), the
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sfunction of the transporter in pancreatic cancer cells has so far not
attracted much attention. In the present study, we have
investigated a potential role for the xc
  transporter in growth,
viability and GSH-based drug resistance of pancreatic cancer,
using human pancreatic cancer cell lines, MIA PaCa-2, PANC-1,
and BxPC-3, in particular as modulated by oxidative stress factors,
changes in extracellular cystine levels and specific xc
  inhibition.
Importantly, pancreatic cancer tissues from patients showed
overexpression of the transporter. Taken together, the results
suggest that the xc
  cystine transporter plays a significant role in
the growth, viability and therapy resistance of pancreatic cancers
and may be useful as a potential target for therapy of the disease.
MATERIALS AND METHODS
Materials
Chemicals, dyes, solvents, solutions and culture medium were
obtained from Sigma-Aldrich Canada Ltd, Oakville, ON, Canada,
unless otherwise indicated.
Maintenance of pancreatic cancer cell cultures
The human pancreatic cancer cell lines, MIA PaCa-2, PANC-1 and
BxPC-3, were originally obtained from the American Type Culture
Collection (Manassas, VA, USA) and maintained as monolayer
cultures in T75 tissue culture flasks (Nunct, Roskilde, Denmark) in
MEM containing 0.1mM cystine (StemCell Technologies, Vancouver,
BC, Canada), supplemented with 10% fetal bovine serum (FBS;
Invitrogen, Carlsbad, CA, USA) and 3.6gl
 1 glucose at 371Ci na
humidified chamber in an atmosphere of 95% air and 5% CO2.
Assessment of growth requirements for exogenous cystine
Cells were plated in 96-well plates (Nunct) at 1000 cells per well
(in triplicate) in their maintenance medium overnight. Cells were
then washed and overlaid with cystine- and methionine-deficient
RPMI-1640 medium supplemented with 10% FBS and 2mM
glutamine, in the presence or absence of cystine (0.1mM),
methionine (0.1mM), and/or cystathionine (0.15mM) in various
combinations. Following 72h of incubation, a neutral red uptake
assay was performed to determine cell survival. It is noteworthy
that normal cystine concentrations in human blood plasma range
between 0.1–0.2mM (Chawla et al, 1984; Gmunder et al, 1991).
Therefore, we defined the normal cystine concentration to be
0.1mM cystine. Accordingly, cystine concentrations lower than
0.1mM or higher than 0.2mM were considered as low or high
cystine concentrations, respectively.
Cell survival/proliferation assay
Cell proliferation and viability were determined by neutral red
uptake (Babich and Borenfreund, 1991). Cells were plated in 96-
well plates at 1000 cells per well. The next day, cells were treated as
dictated by the particular experiments. Wells were then aspirated
and incubated with 100ml 0.0025% neutral red dye in cell culture
medium. Empty wells were also incubated with neutral red dye to
allow for background absorbance correction. After 4h of incuba-
tion, wells were aspirated and 100ml 1% acetic acid in 50% ethanol
was added per well to solubilise intracellular neutral red dye.
Absorbance was determined at 550nm using a 96-well VERSA max
microplate reader (Molecular Devices, Sunnyvale, CA, USA).
RNA isolation and q-RT–PCR
Isolation of total RNA from cultured cells in vitro or tumour
cells in vivo was performed using an RNeasy Micro kit (Qiagen
Inc., Valencia, CA, USA) according to the manufacturer’s
recommendations. RNA (5mg) was used to synthesise first-strand
cDNA using the Superscript II RT–PCR kit (Invitrogen), accord-
ing to the manufacturer’s recommendations. q-RT–PCRs were
performed in 384-well plates using SYBR
s Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA) in a volume of 15ml
(containing 50ng of cDNA). Fluorescence emission was detected
for each PCR cycle on a ABI Prism
s 7900 Sequence Detection
System (Applied Biosystems) and threshold cycle (Ct) values were
determined based on a 40-cycle reaction. Thermal cycling
conditions were 501C for 2min and 951C for 5min, followed by
40 cycles of 15s at 951C, 30s at 581C, and 30s at 721C. Average Ct
values from duplicate PCRs were normalised to average Ct values
for the housekeeping gene b-2-microglobulin (b2M) from the same
cDNA preparations. The relative mRNA expression of a gene was
calculated as follows: Average Ct (b2M) Average Ct (gene)¼d;
mRNA expression relative to b2M¼2^(d). Each q-RT–PCR was
carried out in duplicate.
Primer sequences are as follows: mouse 4F2hc: forward
50-GAGGACAGGCTTTTGATTGCAG-30, reverse 50-AGGTAGGAGC
TGGTCAACAGCA-30; mouse xCT: forward 50-GAGGACAGGCTTT
TGATTGCAG-30, reverse 50-AGGTAGGAGCTGGTCAACAGCA-30;
mouse b2M: forward 50-CACCCCCACTGAGAGACTGATACA-30,
reverse 50-TGATGCTTGATCACATGTCTCG-30; human 4F2hc:
forward 50-AGTGCCAACATGACTGTGAAG-30, reverse 50-CCTTA
CTCCGCTGGTCACTCAG-30; human xCT: forward 50-TGCTGGCT
GGTTTTACCTCAAC-30, reverse 50-CCAATGGTGACAATGGCC
AT-30; human b2M: forward 50-ACCATGTGACTTTGTCACAGC
C-30, reverse 50-AATCCAAATGCGGCATCTTC-30.
Glutathione assay
Total GSH levels were measured using the ApoGSHt GSH
Colorimetric Detection Kit (BioVision, Mountain View, CA,
USA) according to the manufacturer’s recommendations.
Western blotting
Total cellular protein was extracted on ice by sonication and
supplemented with a protease inhibitor solution (one tablet of
Complete Protease Inhibitor Cocktail dissolved in 25ml of 1 
PBS) (Roche, Basel, Switzerland).
Protein samples (10mg) were electrophoresed under reducing
conditions on NuPAGE 4–12% bis-Tris gels and transferred to
0.45-mm nitrocellulose membranes (Invitrogen). Membranes were
blocked overnight at 41C with 10% skim milk in 1  PBS, followed
by incubation with the following primary antibodies: mouse anti-
human 4F2hc (Chemicon, Temecula, CA, USA; 1:250 dilution) and
mouse anti-human a-tubulin (Sigma, 1:10000 dilution). After
incubation for 1h, membranes were washed and incubated with
the secondary antibodies: horse radish peroxidase-linked anti-
mouse (Jackson ImmunoResearch Laboratories Inc., West Grove,
PA, USA; 1:10000 dilution) or horse radish peroxidase-linked
anti-rabbit IgG (Jackson ImmunoResearch Laboratories; 1:2000
dilution). After incubation for 1h, Amersham (GE Healthcare,
Piscataway, NJ, USA) ECL Plust western blotting detection
reagents were used for visualisation.
Immunofluorescence microscopy
Pancreatic cancer cells used for immunocytochemistry were
cultured on glass chamber slides. Cells were washed two times in
PBS and fixed in 4% paraformaldehyde for 10min. Following three
washes in PBS and 30min incubation in blocking solution (PBS
plus 5% goat serum plus 0.1% Triton X-100), cells were incubated
with rabbit anti-mouse xCT antibody (Transgenic Inc., Kumamoto,
Japan; 1:50 dilution) or mouse anti-human 4F2hc antibody
(Chemicon; 1:200 dilution), diluted in blocking solution for
45min at 41C. Cells were then rinsed three times with blocking
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ssolution and incubated with either goat anti-mouse or goat anti-
rabbit AlexaFluor
s594 (Invitrogen; 1:100 dilution) for 30min in
the dark. Finally, cells were washed, stained with 406-diamidino-2-
phenylindole (DAPI) and mounted with Vectashield
s (Vector
Laboratories, Burlingame, CA, USA). Immunofluorescence was
detected with an Axiovert 40 imaging microscope (Carl Zeiss
Canada, Toronto, ON, Canada), and images were captured with a
AxioCam HRC digital camera (Carl Zeiss). Merged images were
generated using Adobe PhotoShop (Adobe Systems, Mountain
View, CA, USA).
Primary human pancreatic tumours and corresponding normal
human pancreatic tissues (gift of Dr Sylvia Ng, BC Cancer Agency,
Vancouver, BC, Canada.) were embedded and frozen in Tissue-
Tek
s optimal cutting temperature compound (Somagen Diagnos-
tics, Edmonton, Alberta, Canada), sectioned at 5-mm thickness
using a CM1850 UV cryostat (Leica, Wetzlar, Germany), and
mounted on Fisherbrand Plus microscope slides. Subsequently,
these samples were subjected to the same immunohistochemical
staining procedures as described for cultured cells. The patient
samples were obtained in agreement with the Ethical Committee of
the University of British Columbia and after obtaining informed
consent from the patients.
Transient transfection
Plasmid constructs of mouse xCT and 4F2hc cDNAs cloned into
the pcDNA3.1
þ vector were transformed into the E.coli strain
DH5a, and plasmid DNA harvested using a Qiagen Maxiprep kit
according to the manufacturer’s recommendations.
For xc
  transporter overexpression studies, pancreatic cancer cells
were plated at a density of 0.5 10
3 cells per well in 96-well plates.
After 24h, wells were aspirated and 125ml of fresh media were
added. Cells were transiently transfected with 0.1mg DNA (empty
vector pcDNA3.1 control, pcDNA3.1-xCT, or pcDNA3.1-4F2hc)
diluted in 12.5ml1 5 0 m M NaCl and 0.75ml ExGen 500 in vitro
transfection reagent (Fermentas, Burlington, ON, Canada) for 24h.
Glutamate uptake assay
Glutamate uptake by cultured cells was used to measure
xc
  transporter activity as described previously (Shih and Murphy,
2001). Briefly, cells were plated in 24-well plates at 5 10
5 cells per
well and incubated overnight. Cells were washed with and
pre-incubated in 1ml per well Na
þ-free buffer A consisting of
140mM N-methyl-D-glucamine, 5.4mM KCl, 0.4mM KH2PO4,
10mM HEPES, 5mMD -glucose, 1.8mM CaCl2, 0.8mM MgSO4
(pH 7.4) for 20min at 371C. The medium was then replaced with
300mlN a
þ-free buffer A containing 33nML -[
3H]-glutamate
(49 Cimmol
 1) (Amersham Pharmacia/GE Healthcare, Pittsburg,
PA, USA) in the presence or absence of 1mM unlabeled amino-
acid competitors (L-glutamate, L-cystine) or non-competitors
(L-leucine) for 20min at 371C. Uptake was terminated by washing
three times with ice-cold Na
þ-free buffer A, after which cells were
solubilised with 200ml 0.5% Triton X-100 in 0.1 M potassium
phosphate buffer (pH 7.0). To determine intracellular L-[
3H]-
glutamate uptake, 100ml of cell lysate was mixed with 5ml of
scintillation cocktail (Fisher, Pittsburg, PA, USA), and radio-
activity was measured using an LKB Wallac 1214 Rackbeta
(American Instrument Exchange Inc., Haverhill, MA, USA) liquid
scintillation counter. A 10ml aliquot of cell lysate was used in a
BCA protein assay kit (Pierce Chemical Co, Rockford, IL, USA) to
determine protein concentration.
Statistical analysis
Student’s t-test was used unless otherwise stated to determine
statistical significance. Results with a Pp0.05 were considered
significant.
RESULTS
Growth requirement for extracellular cystine
It is known that cysteine, the reduced form of cystine, is a non-
essential amino acid in the human diet as tissues in the body such
as the liver can generate cysteine through the transsulphuration
pathway (Stabler et al, 1993; Brosnan and Brosnan, 2006). This
pathway involves the metabolism of methionine, a nutritionally
essential amino acid, to a cystathionine intermediate and its
subsequent cleavage by g-cystathionase to a-ketobutyrate and
cysteine (Stabler et al, 1993; Brosnan and Brosnan, 2006). Certain
cancer cells cannot generate their own cysteine/cystine and hence
depend on extracellular sources to sustain growth and survival
(Iglehart et al, 1977; Gout et al, 2001). To determine if pancreatic
cancer cells require exogenous cystine for growth and survival, we
cultured MIA PaCa-2, PANC-1, and BxPC-3 in the presence and
absence of cystine, methionine, and/or cystathionine in all possible
combinations. Survival and robust growth of all three cancer cell
lines was observed only in cultures containing both methionine
and cystine (Figure 1), demonstrating that the absence of either
amino acid inhibited survival and proliferation in vitro. Cystathio-
nine, which can substitute for cystine in some cell systems
(Uren and Lazarus, 1979), failed to promote cell survival/growth
when added to cystine-deficient, methionine-containing cultures
(Figure 1). These results indicate that pancreatic cancer cell lines
are dependent on uptake of cystine from their microenvironment
for growth and survival, and suggest that the enzymes involved
in the transsulphuration pathway may not be present or activated
in these cells.
A negative correlation exists between extracellular cystine
deprivation and expression of the xc
  transporter
The xc
  transporter is a major transporter of extracellular cystine
(Bannai, 1984b). To determine whether extracellular cystine
concentrations affect the expression of the xc
  transporter,
pancreatic cancer cells were incubated in a medium containing
low (0.01mM), normal (0.1mM) or high (1.0mM) levels of cystine
for up to 72h. Cells in media containing low cystine exhibited
signs of death after 72h (data not shown). The xc
  transporter is
structurally composed of an xCT light subunit, which confers
substrate specificity and a 4F2hc heavy subunit, which is a
common subunit of many amino-acid transporters (Sato et al,
1999; Bassi et al, 2001). The mRNA expression levels of the xCT
and 4F2hc subunits at varying cystine concentrations were
determined by quantitative real-time RT–PCR (q-RT–PCR). In
response to low cystine concentrations, xCT mRNA was elevated in
two of the three cell lines (MIA PaCa-2 and PANC-1), whereas
4F2hc mRNA was elevated in all three cell lines (MIA PaCa-2,
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Figure 1 Pancreatic cancer cells depend on extracellular cystine for
growth. Neutral red uptake assay for cell proliferation in MIA PaCa-2,
PANC-1, and BxPC-3 cells incubated in medium in the presence or
absence of methionine (0.1mM), cystine (0.1mM), and/or cystathionine
(0.15mM), in the combinations indicated for 72h. Data represent the
mean±s.e.m. from three independent experiments. *Po0.01.
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sPANC-1 and BxPC-3) (Figure 2A). Expression of 4F2hc protein in
all three cell lines was determined by western blot analysis and
yielded a similar increased expression level in response to low
cystine concentration (Figure 2B). Unfortunately, no satisfactory
xCT antibody for western blotting was available at the time these
experiments were conducted, thus precluding the examination of
xCT protein expression in our studies. These findings demonstrate
that inverse correlations exist between extracellular cystine
concentration and both xCT and 4F2hc expression in some
pancreatic cancer cell lines, suggesting that these cells can
modulate the expression of xc
  transporter to accommodate their
growth needs.
Oxidative stress increases xc
  transporter expression and
GSH levels
The oxidative stressor, diethylmaleate (DEM), is commonly used
to regulate intracellular GSH levels (Bannai, 1984a; Kim et al, 2001;
Hosoya et al, 2002) and is often used to induce the expression of
stress response-related genes. All three pancreatic cancer cell lines
were treated with 1mM DEM for 24h, and an increase in total
intracellular GSH levels in response to DEM treatment was
confirmed (Figure 3A). In a blood–brain barrier cell line,
treatment with DEM increased GSH levels with a corresponding
increase in xCT mRNA expression (Hosoya et al, 2002). To
determine whether the DEM-induced increase in GSH levels in
pancreatic cancer cells corresponded with an increase in xc
 
transporter expression, mRNA expression levels of xCT and 4F2hc
were determined by q-RT–PCR. xCT mRNA expression was
significantly upregulated in all three cell lines in response to DEM
(Figure 3B). In contrast, 4F2hc mRNA remained at control levels
(Figure 3B), consistent with previous studies that reported no
effect of DEM on 4F2hc mRNA expression in a rat retinal capillary
endothelial cell line (Tomi et al, 2002) and a human retinal
pigment epithelial cell line (Bridges et al, 2001). Corresponding
4F2hc protein levels also remained unchanged in response to
DEM treatment (Figure 3C). To assess xCT protein expression,
immunofluorescent staining with an anti-xCT antibody was
performed on pancreatic cancer cell lines. Increased xCT protein
levels were observed in all three pancreatic cancer cell lines in
response to DEM treatment, with the BxPC-3 cell line exhibiting a
clear localisation of the xCT protein to the plasma membrane upon
treatment with DEM (Figure 3D). These findings suggest that
pancreatic cancer cells, in response to oxidative stress, upregulate
expression of the xc
  transporter by inducing xCT (but not 4F2hc)
subunit expression, resulting in a corresponding increase in GSH
synthesis. This increase in GSH synthesis may in turn enable
pancreatic cancer cells to survive in the presence of elevated levels
of reactive oxygen species.
Expression of the xc
  transporter in primary human
pancreatic cancer specimens
Having demonstrated that pancreatic cancer cell lines express the
xc
  transporter, its expression was assessed in primary human
pancreatic cancer tissues. Owing to difficulties in obtaining fresh
human pancreatic cancer tissues, only two patient samples were
used in this study. Both pancreatic cancer patient specimens with
corresponding normal pancreatic tissue from the same patient
were stained with anti-xCT antibody by immunofluorescence. Use
of a rabbit IgG antibody as a negative control indicated that the
xCT staining was not due to non-specific binding of immuno-
globulins. In the normal pancreatic tissues, xCT protein expression
was primarily localised to ductal cells, not acinar cells (Figure 4).
Importantly, the pancreatic ductal adenocarcinomas exhibited
overexpression of xCT protein. The distinct histological features of
the two pancreatic cancer specimens, including atypical epithelial
architecture, papillary folding, and intraluminal cell shedding,
indicated that these specimens were likely invasive pancreatic
ductal adenocarcinomas. The upregulated expression of xCT
protein in the pancreatic cancer tissues suggest that elevated
xc
  transporter expression plays a role in the pathogenesis of
pancreatic cancer.
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Figure 2 A negative correlation exists between extracellular cystine deprivation and expression of the xc
  transporter. (A) Q-RT–PCR for expression of
xCT or 4F2hc mRNA in MIA PaCa-2, PANC-1, and BxPC-3 cell lines incubated with various cystine concentrations (0.01, 0.1 or 1mM) for 72h. Data
represent the mean±s.e.m. from three independent experiments. *Pp0.05. (B) Western blot for expression of 4F2hc or tubulin in MIA PaCa-2, PANC-1,
and BxPC-3 cell lines incubated with various cystine concentrations (0.01, 0.1 or 1mM) for 72h. Results are representative of two independent experiments.
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of xCT and resistance towards GEM
Thus far we have obtained evidence that elevated xc
  transporter
expression can enhance pancreatic cancer cell growth by promot-
ing the uptake of extracellular cystine, which in turn functions to
maintain high levels of intracellular GSH to promote cancer cell
survival in the presence of oxidative stress. Among the three
pancreatic cancer cell lines used in this study, PANC-1 cells
expressed the highest relative level of xCT mRNA compared with
that of BxPC-3 and MIA PaCa-2 (Figure 5A), suggesting that
PANC-1 cells may exhibit the greatest resistance towards oxidative
stress-induced cell death. Gemcitabine, the most common
chemotherapeutic agent for the treatment of pancreatic cancer
(Maehara et al, 2004), induces cell death through a mechanism that
can involve oxidative stress (Maehara et al, 2004; Donadelli et al,
2007). To determine whether a relationship exists between the
expression level of the xc
  transporter and resistance towards GEM,
we treated pancreatic cancer cells with GEM and determined the
half maximal inhibitory concentration (IC50) of GEM using neutral
red assays. The IC50 of GEM was highest in PANC-1 cells (450mM)
compared with MIA PaCa-2 (B0.03mM) and BxPC-3 (0.01mM) cells
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Figure 3 Oxidative stress increases xc
  transporter expression and GSH levels. (A) Intracellular GSH levels in MIA PaCa-2, PANC-1, and BxPC-3 cell lines
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independent experiments. (D) Immunofluorescence for xCT (red) and DAPI (blue) in MIA PaCa-2, PANC-1, and BxPC-3 cell lines either untreated or
treated with 1mM DEM for 24h. Results are representative of two independent experiments.
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Figure 4 Expression of the xc
  transporter in primary human pancreatic cancer specimens. Immunofluorescence for xCT (red) and DAPI (blue) in normal
ductal cells, normal acinar cells, and pancreatic ductal adenocarcinoma cells from two primary human pancreatic cancer patient specimens.
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s(Figure 5B). The higher resistance of the PANC-1 cells to GEM may
correspond with the higher number of cystine transporters per cell
as suggested by relative xCT expression levels. Hence a negative
correlation exists between the expression level of xCT and
sensitivity to GEM; PANC-1 cells, which have highest relative
expression of xCT, are the least sensitive to GEM, whereas MIA
PaCa-2 cells, which have the lowest relative expression of xCT, are
the most sensitive to GEM.
Overexpression of transfected xCT increases cystine
uptake and increases GEM resistance
To determine if overexpression of the xc
  transporter can increase
resistance to GEM, xCT and 4F2hc cDNAs were transfected into
the pancreatic cell lines MIA PaCa-2 and PANC-1. Increased xCT
and 4F2hc mRNA expression was confirmed by semi-quantitative
RT–PCR and q-RT–PCR in transfected MIA PaCa-2 (Figure 6A–C)
and PANC-1 (data not shown) cell lines. Using a radioactive
glutamate uptake assay, MIA PaCa-2 cells transfected with either
xCT cDNA alone or both xCT and 4F2hc cDNA exhibited increased
xc
  transport activity (Figure 6D). Transfection of 4F2hc cDNA
alone, however, was not sufficient to upregulate xc
  transporter
activity (Figure 6D). Furthermore, transfection of both xCT and
4F2hc cDNA was required to increase GEM resistance in MIA
PaCa-2 cells (Figure 6E). Hence upregulation of the xCT subunit
expression is necessary to upregulate xc
  transporter activity, with
a corresponding increase in GEM resistance. These results suggest
that overexpression of the xc
  transporter, as seen in primary
pancreatic ductal adenocarcinoma specimens, may increase
pancreatic cancer cell survival in response to GEM treatment.
Targeting xc
  transporter function with monosodium
glutamate
Monosodium glutamate (MSG) is a specific inhibitor of the xc
 
transporter as the uptake of cystine can be competitively inhibited
by glutamate (Bannai, 1986). Consistent with this, pancreatic
cancer cells treated with MSG (4.0mM) exhibited markedly
inhibited growth, with growth of MIA PaCa-2 and PANC-1
cultures completely abrogated. Importantly, the growth arrest
could be largely prevented by including 2-mercaptoethanol (2-ME;
66mM) in the culture medium, a compound commonly used to
shuttle cystine into cells through the L-transport system hence
circumventing inhibition of the xc
  transporter (Ishii et al, 1981)
(Figure 7). Taken together, our findings demonstrate that the
growth of pancreatic cancer cells can be inhibited by specific
inhibition of the xc
  transporter.
DISCUSSION
The xc
  transporter has been shown in various cancers to supply
cells with cystine for GSH synthesis resulting in increased
proliferation and GSH-related drug resistance (Doxsee et al,
2007; Narang et al, 2007). The goal of this study was to investigate
whether a similar xc
 -mediated system was also used by pancreatic
cancer cells for growth, survival and drug-related resistance.
In the present study, the human pancreatic cancer cell lines MIA
PaCa-2, PANC-1, and BxPC-3 were determined to be critically
dependent on extracellular cystine for growth (Figure 1). This
finding demonstrates that the biochemical cysteine synthesis
pathway known as the transsulphuration pathway does not
participate in alleviating cystine depletion in the cell lines of this
study. Some cell types, such as neurons and astrocytes, do not rely
on the xc
  transporter for growth (Chung et al, 2005). As such,
these cells may (i) possess a functional transsulphuration pathway,
(ii) express other transporters that mediate the transport of cystine
or cysteine into the cell, for example, excitatory amino-acid
transporters (McBean and Flynn, 2001), or (iii) not express the
xc
  transporter, but instead rely solely on uptake of extracellular
cysteine secreted by certain somatic cells (Gout et al, 2001; Chung
et al, 2005; Lo et al, 2008). The potential utility of screening
tumour biopsies for the presence of enzymes in the transsulphura-
tion pathway (i.e., for g-cystathionase) to determine whether a
patient may benefit from cystine starvation therapy remains
a possibility.
Because our results indicate that pancreatic cancer cell lines are
dependent on extracellular cystine/cysteine for growth, these cell
lines may exhibit sensitivity towards depletion of the amino acid in
their environment. Indeed, at least two of the three cell lines tested
showed an inverse correlation between a low extracellular cystine
environment (0.01mM) and expression of the xc
  transporter,
suggesting that these cells can modulate their expression of the xc
 
transporter to accommodate their growth needs. Consistent with
published reports, cell proliferation is strongly associated with
cystine/cysteine availability and intracellular GSH levels (Godwin
et al, 1992; Noda et al, 2002).
Besides manipulating cysteine/cystine levels in the extracellular
microenvironment to effect a change in xc
  transporter expression,
the addition of the oxidative stressor DEM was also used. In
accordance with other studies (Bannai, 1984a; Kim et al, 2001;
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sHosoya et al, 2002), DEM treatment induced xCT mRNA
expression with a corresponding increase in total GSH, indicating
that increased intracellular GSH synthesis enables pancreatic
cancer cells to survive in the presence of oxidative stress. In
human embryonic kidney (HEK) cells, xCT expression has been
reported at the plasma membrane (Shih and Murphy, 2001). Of
interest is the BxPC-3 cell line, which upon treatment with DEM,
clearly exhibited localisation of the xCT subunit to the plasma
membrane (Figure 3D). The 4F2hc subunit is known to translocate
other light subunits to the plasma membrane for functional
activity to occur (Chillaron et al, 2001; Verrey et al, 2004),
suggesting that xCT subunits located in the plasma membrane of
BxPC-3 cells are likely functional. The fact that prominent xCT
protein localisation to the plasma membrane was not seen in the
other cell lines tested may be explained by the observation that
BxPC-3 cells morphologically grow in tighter groups of cells,
facilitating the visualisation of xCT protein at cell–cell (inter-
cellular) plasma membrane junctions. In contrast to BxPC-3 cells,
DEM induced upregulation of xCT protein in MIA PaCa-2 and
PANC-1 cells within the intracellular compartment (Figure 3D).
Indeed, subcellular localisation studies of xCT in HEK cells have
reported xCT expression not only at the plasma membrane, but
also at intracellular membranes such as the lysosomal or
endosomal membranes (Shih and Murphy, 2001). The functional
significance of intracellular xCT expression, however, remains to
be determined.
Although use of the oxidative stressor DEM was able to increase
xCT expression, it did not have an effect on 4F2hc mRNA or
protein expression (Figure 3B and C). The xCT promoter region
contains an antioxidant response element (ARE) that regulates
transcription of the gene (Wasserman and Fahl, 1997; Ishii et al,
2000). In contrast, the presence of an ARE has not been reported in
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sthe 4F2hc promoter region, suggesting a possible explanation for
the observed difference in response to oxidative stress for the two
genes. Alternatively, basal levels of 4F2hc may be much higher
than those of xCT, potentially rendering changes in 4F2hc
expression undetectable. Indeed, in a blood–retinal barrier cell
line, mRNA levels of 4F2hc were reported to be 56-fold higher than
those of xCT (Tomi et al, 2002). This suggests that 4F2hc mRNA in
some cells is in excess, most likely because of the fact that 4F2hc is
a common component of many other amino-acid transport
systems.
Among normal tissues, xCT is expressed predominantly in
normal pancreas (Bassi et al, 2001; Kim et al, 2001), specifically in
the islet cell population (Bassi et al, 2001). Furthermore, xCT has
also been reported to exhibit higher expression in an acinar cell
line compared with a pancreatic islet cell line (Sato et al, 1998).
The present study shows that xCT is expressed in normal
pancreatic tissues preferentially in the ductal cells compared with
the acinar cells. Importantly, in primary human pancreatic ductal
adenocarcinoma specimens, xCT protein is overexpressed
throughout the cancerous ductal structures (Figure 4). Given that
the xc
  transporter is overexpressed in pancreatic cancers, and that
expression of the xc
  transporter can be induced in pancreatic
cancer cell lines in response to oxidative stress, our findings
implicate the xc
  transporter as an important mediator of
pancreatic cancer cell proliferation and survival.
The higher xCT expression by the PANC-1 cells suggest that they
have more xc
  cystine transporters per cell than the other cells and
hence a greater ability to take up cystine from the microenviron-
ment, likely synthesising more GSH when needed. It has been
reported that NIH3T3 cells treated with sublethal levels of DEM to
induce ROS defense genes such as xCT and glutathione-S-
transferase a1 (GSTa1) are associated with higher resistance to
various apoptotic stimuli such as buthionine sulphoximine,
ultraviolet, and etoposide (Faraonio et al, 2006). Moreover, HT22
hippocampal cells resistant to oxidative stress exhibited a 7-fold
overexpression of xCT mRNA, with a concomitant increase in
resistance to glutamate-induced oxidative stress and hydrogen
peroxide-induced oxidative stress (Lewerenz et al, 2006). In the
present study, although PANC-1 cells express a 3.5-fold higher
level of xCT mRNA compared with the MIA PaCa-2 and BxPC-3
cell lines, PANC-1 cells are B1000  more resistant to GEM. This
suggests that GEM resistance cannot be solely explained by higher
xCT mRNA expression, but rather that additional GEM resistance
mechanisms are at play. Nonetheless, overexpressing xCT and
4F2hc in pancreatic cancer cells resulted in an overall increase in
the GEM resistant phenotype (Figure 6). The fact that over-
expressing the xc
  transporter was able to increase cell survival
even in the absence of GEM treatment highlights the importance of
the xc
  transporter as a regulator of pancreatic cancer cell
proliferation and survival. Furthermore MSG, a potent and specific
inhibitor of the xc
  transporter (Bannai, 1986), significantly
inhibited the growth of the pancreatic cancer cell lines. By
including 2-ME (66mM) in the culture medium, which provides an
alternative route for cystine uptake through L-transport system
(Ishii et al, 1981), growth arrest was prevented. This gives direct
evidence that the pancreatic cancer cell lines critically depend on
the xc
  transporter for growth and survival. Unfortunately, MSG
cannot be used for therapy as it is neurotoxic (Choi, 1988).
Our results demonstrate that pancreatic cancer cells exhibit
upregulated expression of the xc
  transporter, which promotes
uptake of extracellular cystine for synthesis of GSH. In turn,
elevated intracellular GSH levels promote pancreatic cancer cell
growth and survival in response to the production of reactive
oxygen species by oxidative stressors, including the chemo-
therapeutic agent GEM. Hence, drug resistance in pancreatic
cancer may be explained in part by overexpression of the xc
 
transporter. Finally, the marked growth arrest of the pancreatic
cancer cell lines obtained through specific inhibition of the xc
 
transporter suggests that this transporter may serve as a target for
therapy of the disease.
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